文献速递前列腺增生与排尿功能障碍

良性前列腺增生药物的全球专利格局

Global Patent Landscape of Benign Prostatic Hyperplasia Drugs.
PubMed 文献 · Urology · 2022-03-18

本研究从Cortellis数据库收集良性前列腺增生(BPH)相关药物的全部专利数据,分析1967年至2019年的1936个专利家族,采用描述性统计、文献计量和引文分析,揭示相关适应症、全球创新中心转移、重要制剂专利及有前景的治疗药物,为相关决策提供参考。

要点

  • BPH药物约20年前首次获批进入主流市场,固定专利期限预示格局可能改变。
  • 研究分析1967年至2019年共1936个专利家族,覆盖相关适应症与制剂专利。
  • 结果涉及全球创新中心转移及有前景的治疗药物,供研究者与临床医生参考。

核心结论

  • BPH药物专利格局正在变化,结果可为研究者、临床医生、政策制定者和投资者提供决策参考。

研究设计与样本

  • 从Cortellis数据库收集所有可获得的BPH相关药物专利数据,采用描述性统计、文献计量分析和引文分析。
  • 分析1967年至2019年的1936个专利家族。

主要发现

  • 研究涉及相关适应症、全球创新中心的转移、值得注意的制剂专利和有前景的治疗药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the changing landscape of BPH drugs by investigating patent documents derived from pipeline projects. Benign prostatic hyperplasia (BPH) drugs were first approved for the mainstream market about 20 years ago. The fixed patent term warns of possibly transforming the landscape of BPH drugs as technological and commercial substitution causes the displacement of established technologies and competitors by newer ones. However, very few studies focus on patents of BPH drugs, though many literature reviews have analyzed this topic from technological and clinical perspectives. METHODS: All available patent data relevant to BPH-related drugs were collected from the Cortellis database. Descriptive statistics, bibliometric analyses, and citation analyses were used to analyze the patent landscape. RESULTS: By analyzing 1,936 patent families from 1967 to 2019, this study addresses the main results on the changing landscape of BPH drugs, involving associated indications, the shifting centers of innovation globally, notable formulation patents, and promising therapeutics. CONCLUSION: The results provide a significant reference for decision-making by researchers, clinicians, policymakers, and investors with an interest in BPH drugs.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Liu K, Yang J, Deng J, et al. Global Patent Landscape of Benign Prostatic Hyperplasia Drugs. Urology. 2022. PMID: 35314182. doi:10.1016/j.urology.2022.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。